Avalon GloboCare Management
Management criteria checks 4/4
Avalon GloboCare's CEO is David Jin, appointed in Sep 2016, has a tenure of 8.25 years. total yearly compensation is $330.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 9.41% of the company’s shares, worth $338.87K. The average tenure of the management team and the board of directors is 8.2 years and 6.4 years respectively.
Key information
David Jin
Chief executive officer
US$330.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 8.3yrs |
| CEO ownership | 9.4% |
| Management average tenure | 8.2yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation
Oct 06
We Think Avalon GloboCare (NASDAQ:AVCO) Has A Fair Chunk Of Debt
Sep 29Would Avalon GloboCare (NASDAQ:AVCO) Be Better Off With Less Debt?
Jun 01Does Avalon GloboCare (NASDAQ:AVCO) Have A Healthy Balance Sheet?
Feb 23Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt
Oct 14Avalon Globocare to acquire SenlangBio in all-stock deal
Jun 14Is Avalon GloboCare (NASDAQ:AVCO) A Risky Investment?
May 15A Look At Avalon GloboCare's (NASDAQ:AVCO) Share Price Returns
Feb 25Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?
Jan 30Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?
Jan 04What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$15m |
| Jun 30 2024 | n/a | n/a | -US$15m |
| Mar 31 2024 | n/a | n/a | -US$15m |
| Dec 31 2023 | US$330k | US$330k | -US$17m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$13m |
| Dec 31 2022 | US$360k | US$360k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$12m |
| Jun 30 2022 | n/a | n/a | -US$8m |
| Mar 31 2022 | n/a | n/a | -US$9m |
| Dec 31 2021 | US$360k | US$360k | -US$9m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$1m | US$360k | -US$13m |
| Sep 30 2020 | n/a | n/a | -US$15m |
| Jun 30 2020 | n/a | n/a | -US$16m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$935k | US$540k | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$15m |
| Jun 30 2019 | n/a | n/a | -US$14m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$400k | US$400k | -US$8m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | n/a | n/a | -US$5m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$200k | US$200k | -US$3m |
Compensation vs Market: David's total compensation ($USD330.00K) is below average for companies of similar size in the US market ($USD646.54K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Jin (56 yo)
8.3yrs
Tenure
US$330,000
Compensation
Dr. David K. Jin, M.D., Ph D., serves as the Chief Executive Officer and President of Avalon Globocare Corp since September 14, 2016. Dr. Jin is a Senior Translational Scientist at the Howard Hughes Medica...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.3yrs | US$330.00k | 9.41% $ 338.9k | |
| Chief Financial Officer | 7.8yrs | US$350.00k | 0% $ 0 | |
| COO & Secretary | 8.2yrs | US$280.24k | 3.14% $ 113.0k |
8.2yrs
Average Tenure
56yo
Average Age
Experienced Management: ALBT's management team is seasoned and experienced (8.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.3yrs | US$330.00k | 9.41% $ 338.9k | |
| Member of Scientific & Clinical Advisory Board | 5.7yrs | no data | no data | |
| Independent Director | 6.4yrs | US$103.67k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$103.67k | 0% $ 0 | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Director | 7.1yrs | US$38.05k | 0% $ 0 | |
| Independent Director | 6.5yrs | US$93.67k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$91.76k | 0% $ 0 | |
| Chairman of the Board | 8.2yrs | US$100.00k | 21.83% $ 786.0k | |
| Head of Scientific & Clinical Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data |
6.4yrs
Average Tenure
60.5yo
Average Age
Experienced Board: ALBT's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:02 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avalon GloboCare Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|